EXEL vs NBIX
Exelixis, Inc. and Neurocrine Biosciences Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | EXEL | NBIX |
|---|---|---|
| Revenue | $2.3B | $2.9B |
| Net income | $782.6M | $478.6M |
| Gross margin | 96.4% | 98.2% |
| Net margin | 33.7% | 16.7% |
| Return on equity | 35.5% | 16.4% |
| Diluted EPS | $2.78 | $4.67 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $875.8M | $748.7M |
| Equity | $2.2B | $3.3B |
| Net debt / equity | · | · |
| Current ratio | 3.56× | 3.39× |
| Revenue CAGR 5y | 18.6% | 22.3% |
| Profit CAGR 5y | 47.6% | 3.3% |
NBIX bills 1.2× the revenue of EXEL, and EXEL keeps more of each dollar of revenue as profit (33.7% against 16.7%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | EXEL | NBIX |
|---|---|---|
| FY2025 | $2.3B | $2.9B |
| FY2024 | $2.2B | $2.4B |
| FY2023 | $1.8B | $1.9B |
| FY2022 | $1.6B | $1.5B |
| FY2021 | $1.4B | $1.1B |
| FY2020 | $987.5M | $1.0B |
| FY2019 | $967.8M | $788.1M |
| FY2018 | $853.8M | $451.2M |
| FY2017 | $452.5M | $161.6M |
| FY2016 | $191.5M | $15.0M |
Bottom line
| Fiscal year | EXEL | NBIX |
|---|---|---|
| FY2025 | $782.6M | $478.6M |
| FY2024 | $521.3M | $341.3M |
| FY2023 | $207.8M | $249.7M |
| FY2022 | $182.3M | $154.5M |
| FY2021 | $231.1M | $89.6M |
| FY2020 | $111.8M | $407.3M |
| FY2019 | $321.0M | $37.0M |
| FY2018 | $690.1M | $21.1M |
| FY2017 | $154.2M | $-142.5M |
| FY2016 | $-70.2M | $-141.1M |
17 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$540,374,000 | NBIX |
| FY2024 | −$186,599,000 | NBIX |
| FY2023 | −$56,892,000 | NBIX |
| FY2022 | +$122,362,000 | EXEL |
| FY2021 | +$301,470,000 | EXEL |
| FY2020 | −$58,362,000 | NBIX |
| FY2019 | +$179,675,000 | EXEL |
| FY2018 | +$402,626,000 | EXEL |
| FY2017 | +$290,851,000 | EXEL |
| FY2016 | +$176,454,000 | EXEL |
| FY2015 | +$17,403,000 | EXEL |
| FY2014 | +$25,111,000 | EXEL |
| FY2013 | +$28,419,000 | EXEL |
| FY2012 | −$5,690,000 | NBIX |
| FY2011 | +$212,223,000 | EXEL |
| FY2010 | +$151,544,000 | EXEL |
| FY2009 | +$148,806,000 | EXEL |
The higher-revenue side has changed between EXEL and NBIX over this period. The gap has widened since the earliest year compared.
17 of 17 comparable fiscal years — a year missing data on either side is not counted.
14 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +17.0 pp | EXEL |
| FY2024 | +9.5 pp | EXEL |
| FY2023 | −1.9 pp | NBIX |
| FY2022 | +0.9 pp | EXEL |
| FY2021 | +8.2 pp | EXEL |
| FY2020 | −27.6 pp | NBIX |
| FY2019 | +28.5 pp | EXEL |
| FY2018 | +76.1 pp | EXEL |
| FY2017 | +122.3 pp | EXEL |
| FY2016 | +903.9 pp | EXEL |
| FY2015 | +14.7 pp | EXEL |
| FY2012 | −315.7 pp | NBIX |
| FY2011 | −22.4 pp | NBIX |
| FY2010 | −26.1 pp | NBIX |
The higher net margin has changed hands between EXEL and NBIX over this period.
14 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NBIX's net margin has been more volatile than EXEL's over the 14 comparable fiscal years — 263.7 percentage points of standard deviation against 140.8.
14 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between EXEL and NBIX over these 14 fiscal years — EXEL led in 9 and NBIX in 5.
14 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
EXEL's return on equity has been more volatile than NBIX's over the 11 comparable fiscal years — 74.1 percentage points of standard deviation against 22.7.
11 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between EXEL and NBIX over these 11 fiscal years — EXEL led in 6 and NBIX in 5.
11 of 17 comparable fiscal years — a year missing data on either side is not counted.